Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 4/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.34 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.34 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.34 |
| ▸ | MGLL | Q99685 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7811779 | 0.87 | SLC6A4 (0.47) | SLC6A4DRD2SLC6A3ALOX5SLC6A2 | |
| SCHEMBL6752313 | 0.76 | SLC6A4 (0.38) | SLC6A4DRD2SLC6A3ALOX5SLC6A2 | |
| SCHEMBL5744613 | 0.76 | SLC6A4 (0.38) | SLC6A4DRD2SLC6A3ALOX5SLC6A2 | |
| SCHEMBL31172103 | 0.74 | SLC6A4 (0.61) | SLC6A4DRD2SLC6A3ALOX5SLC6A2 | |
| SCHEMBL28359596 | 0.74 | SLC6A4 (0.61) | SLC6A4DRD2SLC6A3ALOX5SLC6A2 | |
| SCHEMBL4670974 | 0.73 | SLC6A4 (0.54) | SLC6A4DRD2SLC6A3ALOX5SLC6A2 | |
| SCHEMBL7865136 | 0.69 | SLC6A4 (0.43) | SLC6A4DRD2SLC6A3ALOX5SLC6A2 | |
| SCHEMBL19393299 | 0.69 | SLC6A4 (0.43) | SLC6A4DRD2SLC6A3ALOX5SLC6A2 | |
| SCHEMBL1607683 | 0.68 | NOS3 (0.40) | — | |
| SCHEMBL20172556 | 0.68 | SLC6A4 (0.39) | SLC6A4DRD2SLC6A3ALOX5SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6376500-B2 | 1-(INDOL-3-YLALKYL)ALKYLPIPERIDIN-4 -YL)-3H-QUINOLIN-4-ONE, FOR EXAMPLE; ALPHA1A/ B-RECEPTOR ANTAGONISTS; SIDE EFFECT REDUCTION; UROGENITAL DISORDERS; BENIGN PROSTATIC HYPERTROPHY; ANALGESICS FOR INFLAMMATORY, NEUROPATHY, CANCER, | SYNTEX (U.S.A.) LLC | 2002-04-23 | — | — | US | disclosed |
| US-20010051627-A1 | Substituted 2-(4-piperidyl)-4(3H)-quinazolinones and 2-(4-piperidyl)- 4(3H)-azaquinazolinones | CLARK ROBIN DOUGLAS (US) | 2001-12-13 | — | — | US | disclosed |
| US-6258819-B1 | BIOLOGICAL RECEPTORS, ANTIINFLAMMATORY AGENTS, BENIGN PROSTATE AND SIDE EFFECT REDUCTION | SYNTEX (U.S.A.) LLC | 2001-07-10 | — | — | US | disclosed |
| WO-2001010860-A2 | QUINAZOLINONE AND AZAQUINAZOLINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010051627-A1 | Substituted 2-(4-piperidyl)-4(3H)-quinazolinones and 2-(4-piperidyl)- 4(3H)-azaquinazolinones | ADRA2B, ADRA1D, ADRA1B | SLC6A4 678/4885DRD2 361/4885SLC6A3 613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.